Characterization and optimization of the ReLiver engineered liver tissue****

该项目将启动维多利亚大学Willerth实验室和魁北克Morphocell技术公司之间的首次合作。Morphocell Technologies是一家再生医学公司，专注于干细胞疗法和工程组织的开发和商业化，旨在治疗肝脏疾病。特别是，该项目将进一步表征和优化他们的ReLiver产品，该产品由人类诱导多能干细胞（hiPSCs）衍生的功能性肝组织组成，称为类器官。ReLiver产品由hipsc衍生的肝组织包裹在聚乙二醇（PEG）涂层内，以促进生物相容性。该项目将使用扫描电子显微镜表征包括孔径在内的性能，并将研究替代生物材料配方以改善涂层性能。Willerth博士在生物材料和基于干细胞的组织工程领域拥有超过15年的经验，使她成为这个项目的合理合作伙伴。******

This project will initiate a first time collaboration between the Willerth laboratory at the University of Victoria**and Morphocell Technologies located in Quebec. Morphocell Technologies is a regenerative medicine company focused on the development and commercialization of stem cell therapies and engineered tissues aimed at treating liver diseases. In particular, this project will enable further characterization and optimization of their ReLiver product - which consists of functional liver tissues derived from human induced pluripotent stem cells (hiPSCs) known as organoids. The ReLiver product consists hiPSC-derived liver tissues encapsulated inside of a poly (ethylene glycol) (PEG) coating that promotes biocomptability. This project will characterize the properties, including pore size, using scanning electron microscopy and will investigate alternative biomaterials formulations to improve the coating properties. Dr. Willerth has over 15 years of experience in the fields of biomaterials and stem cell-based tissue engineering, making her a logical partner for this project.******